tislelizumab + concurrent chemoradiotherapy

This combination regimen consists of tislelizumab (BGB-A317), a humanized IgG4 monoclonal antibody targeting the programmed cell death protein-1 (PD-1) receptor, administered in conjunction with concurrent chemoradiotherapy (cCRT). Tislelizumab is specifically engineered to minimize binding to Fcγ receptors on macrophages, a design intended to reduce antibody-dependent phagocytosis and potentially enhance anti-tumor immune responses. In the Phase 3 RATIONALE 001 trial sponsored by Celgene (now part of Bristol Myers Squibb), this regimen is evaluated for patients with newly diagnosed, locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). The cCRT component typically involves platinum-based chemotherapy (such as cisplatin plus etoposide or carboplatin plus paclitaxel) and concurrent radiotherapy targeting a total dose of 60 Gy. The treatment strategy often includes a maintenance phase of tislelizumab monotherapy following the completion of the concurrent chemoradiotherapy phase.

Brand names

Tevimbra

Other names

concurrent chemoradiotherapy-Celgene-non-small cell lung cancertislelizumab + cCRTBGB-A317 + cCRTRATIONALE 001 regimenRATIONALE001 regimenRATIONALE-001 regimen